{'fraction_non_alphanumeric': 0.028824833702882482, 'fraction_numerical': 0.009608277900960829, 'mean_word_length': 5.509615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MACROPROLACTINEMIA: CLINICAL SIGNIFICANCE AND CHARACTERIZATION OF THE CONDITION

Abstract The purpose of this study was to characterize the clinical picture of macroprolactinemic patients and to further assess whether macroprolactinemia was part of an auto-immune syndrome. Eighty-two hyperprolactinemic (serum PRL > 1000 mU/l) patients were investigated and the PEG precipitation test identified 14 patients with macroprolactinemia. They were submitted to a hormonal and autoimmune screening and an IV TRH test. Bioactivity of their serum prolactin was evaluated, using an Nb2 assay. The biochemical nature of bb-PRL was investigated by immunoprecipitation with anti-IgG antibodies. Seventy-nine percent of the studied patients presented with infertility, amenorrhoea, galactorrhoea, mastodynia, gynaecomastia or erectile dysfunction. In most cases, however, these symptoms could be explained by the presence of other non hyperprolactinemia-related pathology. Despite the finding of in vitro biological activity in all macroprolactinemic sera tested, our results suggest a variable in vivo bioactivity of bb-PRL, probably related to a reduced capacity to cross vascular endothelium. In this study, we demonstrated that in 12 out of 13 samples (85 %), bb-PRL consisted of PRL-IgG complexes. There was no clinical or laboratory evidence of auto-immunity.